Equity Research Biotechnology

Should You Buy BeyondSpring Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 1/13 models active

According to the CirclFi Deep Alpha Valuation Engine, BeyondSpring Inc. (BYSI) presents a moderate quality profile with a QOC score of 4.4/10. Trading at $0.75, separating genuine undervalued opportunities from value traps is essential, as detailed by our model data.

The short answer: 0 of 1 CirclFi valuation models project upside for BeyondSpring Inc. (BYSI) at $0.75 — the model consensus leans bearish, with a Quality Score of 4.4/10 and Value-Trap risk of 28/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 1 of 1 models suggest overvaluation — majority bearish
  • Quality Score: 4.4/10 — Weak — below-average fundamentals
  • Value Trap Risk: 28/100 — Low — manageable risk
  • Fair Value Range: $0.48 – $0.48 (0% spread)

Bullish Models

0 / 1

Bearish Models

1 / 1

Quality Score

4.4 /10

Weak — below-average fundamentals

Value Trap Risk

28 /100
Low

Low — manageable risk

Model Consensus

1 /13
Active Models

Avg. confidence: 39%

What Is the Investment Case for BeyondSpring Inc. (BYSI) in 2026?

What Is the Bull Case vs the Bear Case for BeyondSpring Inc. (BYSI)?

Bull case versus bear case for BeyondSpring Inc. (BYSI) at $0.75, derived from 1 active CirclFi valuation models on 2026-09-15.
Bull case Bear case — $0.48 target (-35.9%)
No active model projects meaningful upside for BYSI at $0.75. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Quality of Company (QOC) framework, BeyondSpring Inc.'s rating of 4.4/10 indicates below-average quality, raising questions about sustainable earnings levels.
According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $0.48 (-35.9%), suggesting that the market price embeds overly optimistic growth assumptions.
Industry headwind: manufacturing scale-up challenges represents a meaningful risk for BeyondSpring Inc. and its Biotechnology peers.

How Does BYSI Compare to Its Biotechnology Peers?

JAGX Jaguar Health, Inc.
4.4
APMD Apnimed, Inc.
4.4
PHIO Phio Pharmaceuticals
4.4
IKT Inhibikase Therapeut
4.4
IBO Impact BioMedical In
4.4
ONCO Onconetix, Inc.
4.3
HALO Halozyme Therapeutic
9.2
OKUR OnKure Therapeutics,
5.9

Valuation data pages: JAGX · APMD · PHIO · IKT · IBO · ONCO · HALO · OKUR · SVRA · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like BYSI on Quality?

Closest companies to BYSI’s Quality of Company score of 4.4/10, across all industries.

Why Do CirclFi’s 1 Models Disagree on BYSI?

Spread

0%

Fair Value Range

$0.48 – $0.48

A tight 0% spread suggests meaningful convergence, strengthening conviction in the composite estimate.

Most Bullish

Regime Cross

$0.48 (-35.9%)

Most Bearish

Regime Cross

$0.48 (-35.9%)

What Are the Biggest Risks of Buying BYSI Stock?

Weak Fundamentals

QOC 4.4/10 signals below-average quality.

Bearish Consensus

1/1 models suggest overvaluation.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View BYSI Data Page →

So Is BeyondSpring Inc. (BYSI) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on BeyondSpring Inc. at $0.75. 1/1 models flag overvaluation, median fair value sits at $0.48 (-35.9%), and the risk-reward profile appears unfavorable. Quality at 4.4/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. BeyondSpring Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About BYSI Stock?

Should I buy BYSI stock right now?

Based on CirclFi's multi-model analysis, 0 of 1 models see upside for BYSI at $0.75. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in BeyondSpring Inc.?

Key risks include: a below-average Quality Score of 4.4/10, indicating fundamental weakness; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does BYSI compare to its competitors?

Among Biotechnology peers, BYSI holds a Quality Score of 4.4/10. Comparable companies include JAGX (QOC 4.4), APMD (QOC 4.4), PHIO (QOC 4.4). The relative ranking helps investors identify whether BYSI offers better fundamental quality than alternatives in the same sector.

Is BYSI a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BYSI's Quality Score of 4.4/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy BYSI at?

CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $0.48 to $0.48. At $0.75, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for BYSI.

View BYSI Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →